Skip to main content
. Author manuscript; available in PMC: 2017 May 3.
Published in final edited form as: Nature. 2016 Sep 5;539(7627):112–117. doi: 10.1038/nature19796

Extended Data Fig. 2. Evaluation of the effects of PT2399 on tumors progressing on sunitinib.

Extended Data Fig. 2

a, Tumor volumes in mice from sensitive lines (XP374 or XP144) switched from vehicle or sunitinib to PT2399 as indicated (bottom black arrows). b, Circulating tumor-produced hVEGF levels in mice treated with vehicle, sunitinib, or sunitinib followed by PT2399. The Wilcoxon rank-sum test was used to determine if sunitinib (n = 4) or sunitinib followed by PT2399 (n = 6) were different than vehicle (n = 4). *, p<0.05. Boxplots have median centre values. c, Representative images of H&E and Ki67 staining of tumors from mice (XP144) treated with vehicle or sunitinib (left panel) and from tumors following a switch to PT2399 (right panel). Scale bars = 100 µM.